CGP 53153: A new potent inhibitor of 5α-reductase

Journal of Steroid Biochemistry and Molecular Biology

Volumn 57, Issue 3-4, 1996, Pages 187-195

  Hausler A ^a   Allegrini, P R ^a   Biollaz, M ^a   Batzl, Ch ^a   Scheidegger, E ^a   Bhatnagar, A S ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CGP 53153; ENZYME INHIBITOR; FINASTERIDE; FLUTAMIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DOG; ENZYME INHIBITION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROSTATE; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0343985317     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(95)00260-X     Document Type: Article

References (17)

1. Wilson J. D. and Gloyna R. E.: The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog. Horm. Res. 26 (1970) 309-336.
2. Wilson J. D.: The pathogenesis of benign prostatic hyperplasia. Am. J. Med. 68 (1980) 745-756.
3. Stoner E., Gregoire S. and Round E. for the finasteride group: Clinical development of finasteride (Proscar®). Drugs of Today 29 (1993) 351-361.
4. Peters D. H. and Sorkin E. M.: Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46 (1993) 177-208.
5. Liang T., Cascieri M. A., Cheung A. H., Reynolds G. F. and Rasmussen G. H.: Species differences in prostatic steroid 5α-reductases of rat, dog and human. Endocrinology 117 (1985) 571-579.
6. + 4-ene-oxido-reductase; EC 1.3.1.22) in a stable and active form. J. Steroid Biochem. Molec. Biol. 38 (1991) 73-77.
7. 50) of an enzymatic reaction. Biochem. Pharmac. 22 (1973) 3099-3108.
8. Dunnett C. W.: A multiple comparison procedure for comparing several treatments with a control. J. Am. Statist. Assoc. 50 (1955) 1096-1121.
9. Dunnett C. W.: New tables for multiple comparisons with a control. Biometrics 20 (1964) 482-491.
10. Bhatnagar A. S., Häusler A., Schieweck K., Lang M. and Bowman R.: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Molec. Biol. 37 (1990) 1021-1027.
11. Di Salle E., Giudici D., Briatico G., Ornati G. and Panzeri A.: Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat. J. Steroid Biochem. Molec. Biol. 46 (1993) 549-555.
12. Cohen S. M., Taber K. H., Malatesta P. F., Shpungin J., Berman C., Carlin J. R., Werrmann J. G., Prahalada S., Bryan R. N. and Cordes E. H.: Magnetic resonance imaging of the efficacy of specific inhibition of 5α-reductase in canine spontaneous benign prostatic hyperplasia. Magn. Reson. Med. 21 (1991) 55-70.
13. Cohen S. M., Werrmann J. G., Rasmusson G. H., Tanaka W. K., Malatesta P. F., Prahalada S., Jacobs J. G., Harris G. and Nett T. M.: Comparison of the effects of new specific azasteroid inhibitors of steroid 5α-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 26 (1995) 55-71.
14. Mooradian A. D., Morley J. E. and Korenman S. G.: Biological actions of androgens. Endocr. Rev. 8 (1987) 1-28.
15. Shin S. H. and Howitt C.: Effect of castration on luteinizing hormone and luteinizing hormone releasing hormone in the male rat. J. Endocr. 65 (1975) 447-448.
16. Browning H. C., Holmber L. M. and White W. D.: Homeostasis of organ weight in response to increasing dosage of testosterone in the castrated mouse. Endocrinology 69 (1961) 901-908.
17. Fadial J. B., Fregly M. J. and Straw J. A.: Requirement of castrated male rats for testosterone propionate. Texas Rep. Biol. Med. 25 (1967) 251-256.